Miflonide Breezhaler (Budesonide)

Budesonide binds to glucocorticoid receptors inside airway cells, altering gene expression to increase anti‑inflammatory proteins and suppress pro‑inflammatory cytokines. This reduces airway edema, mucus secretion, and hyper‑responsiveness, leading to smoother airflow and fewer asthma or COPD symptoms.

The prescribed dose of Miflonide Breezhaler is individualized by a healthcare professional based on disease severity, age, and response to therapy. Patients should follow the exact inhalation instructions provided by their prescriber and not adjust the dose without medical guidance.

Safety data for budesonide inhalation during pregnancy and lactation are limited. The prescriber will weigh potential benefits against risks. If treatment is essential, the lowest effective dose is usually recommended, and breastfeeding mothers should discuss possible infant exposure with their doctor.

To request Miflonide Breezhaler, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Miflonide Breezhaler delivers budesonide via a dry‑powder Breezhaler device, offering rapid lung deposition and convenient dosing. Compared with metered‑dose inhalers of fluticasone or beclomethasone, budesonide has a similar efficacy profile but may have a slightly lower systemic absorption, potentially reducing the risk of systemic side effects.

Store Miflonide Breezhaler at ambient temperature, below 25 °C, in its original sealed container. Protect the device from moisture, excessive heat, and direct sunlight. Keep out of reach of children and avoid exposing the inhaler to freezing conditions.

The patient inhales the powdered medication through the Breezhaler device, following a full exhalation, a deep inhalation through the mouthpiece, and a breath‑hold for several seconds. After each dose, the inhaler should be rinsed with water and the mouth cleared to reduce the risk of oral thrush.

Serious risks include severe allergic reactions (anaphylaxis), paradoxical bronchospasm, pneumonia, and long‑term effects such as reduced bone mineral density or cataract formation. Patients should seek immediate medical attention if they experience swelling of the face, throat, or difficulty breathing.

Miflonide Breezhaler is contraindicated in individuals with known hypersensitivity to budesonide or any component of the inhaler. It should also be avoided in patients with active, untreated respiratory infections unless directed by a physician, and in those for whom systemic corticosteroid therapy is contraindicated.